Abstract
The past 10 years have seen major changes in the way we look at COPD and how we manage this disease. At present, we still have yet to find a therapy that changes the prognosis or reverses disease progression [1], with smoking cessation being the only effective intervention to achieve this. Bronchodilators are currently the main treatment used for the relief of breathlessness in COPD but they do not directly affect the underlying disease process, even though they are effective at reducing exacerbation rates. Long-acting bronchodilators are the preferred therapy, including the anticholinergic (anti-muscarinic) tiotropium bromide and LABAs (salmeterol and formoterol).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Barnes PJ, Stockley RA. COPD: current therapeutic interventions and future approaches. Eur Respir J 2005; 25:1084–1106.
van Noord JA, Aumann JL, Janssens E, et al. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J 2005; 26:214–222.
Cazzola M, Matera MG. Emerging inhaled bronchodilators: an update. Eur Respir J 2009; 34:757-769.
Calverly PM, Anderson JA, Celli B, et al; TORCH investigators. Salmeterol and flutica¬sone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356:775–789.
The Tobacco Use and Dependence Clinical Practice Guideline Panel, Staff, and Consortium Representatives. A clinical practice guideline for treating tobacco use and dependence: A US Public Health Service report. JAMA 2000; 283:3244–3254.
Gonzales D, Rennard SI, Nides M, et al; Varenicline Phase 3 Study Group. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006; 296:47-55.
Jorenby DE, Hays JT, Rigotti NA, et al; Varenicline Phase 3 Study Group. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustainedrelease bupropion for smoking cessation: a randomized controlled trial. JAMA 2006; 296:56-63.
Barnes PJ. Reduced histone deacetylase in COPD: clinical implications. Chest 2006; 129:151–155.
Barnes PJ. Theophylline in chronic obstructive pulmonary disease: new horizons. Proc Am Thorac Soc 2005; 2:334–339.
Ford PA, Durham A, Russell RE, et al. Treatment effects of low dose theophylline combined with an inhaled corticosteroid in COPD. Chest 2010;137(6):1338–1344.
Cosio BG, Iglesias A, Rios A, et al. Low-dose theophylline enhances the anti-inflammatory effects of steroids during exacerbations of COPD. Thorax 2009; 64:424-429.
Barnes PJ, Hansel TT. Prospects for new drugs for chronic obstructive pulmonary disease. Lancet 2004; 364:985–996.
Sturton G, Persson C, Barnes PJ. Small airways: an important but neglected target in the treatment of obstructive airway diseases. Trends Pharmacol Sci 2008;29:340-345.
Fan CK. Phosphodiesterase inhibitors in airways disease. Eur J Pharmacol 2006; 533:110–117.
Barnes PJ. Frontrunners in novel pharmacotherapy of COPD. Curr Opin Pharmacol 2008; 8:300-307.
Barnes PJ. Mediators of chronic obstructive pulmonary disease. Pharm Rev 2004; 56:515–548.
Thiberville L, Salaun M, Lachkar S, et al. Human in vivo fluorescence microimaging of the alveolar ducts and sacs during bronchoscopy. Eur Respir J 2009;33:974-985.
van Noord JA, Cornelissen PJ, Aumann JL, et al. The efficacy of tiotropium administered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients. Respir Med 2009; 103:22-29.
Lomas DA, Silverman EK. The genetics of chronic obstructive pulmonary disease. Respir Res 2001; 2:20–26.
Bach PB, Brown C, Gelfand SE, et al; American College of Physicians–American Society of Internal Medicine; American College of Chest Physicians. Management of acute exacerbations of chronic obstructive pulmonary disease: a summary and appraisal of published evidence. Ann Intern Med 2001; 134:600–620.
Liu BQ, Peto R, Chen ZM, et al. Emerging tobacco hazards in China: 1. Retrospective proportional mortality study of one million deaths. BMJ 1998; 317:1411–1422.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2011 Springer Healthcare, a part of Springer Science+Business Media
About this chapter
Cite this chapter
Russell, R., Ford, P., Barnes, P. (2011). The Future of COPD. In: Managing COPD. Springer Healthcare, Heidelberg. https://doi.org/10.1007/978-1-908517-61-6_6
Download citation
DOI: https://doi.org/10.1007/978-1-908517-61-6_6
Published:
Publisher Name: Springer Healthcare, Heidelberg
Print ISBN: 978-1-85873-449-1
Online ISBN: 978-1-908517-61-6
eBook Packages: MedicineMedicine (R0)